RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, ...
The rapid development of China's RAS-targeted cancer drugs could reshape global oncology and unlock the country's undervalued ...
BioCompute expands funding to innovate DNA data storage, aiming for efficient, sustainable long-term archival solutions for ...
Check Point researchers have identified a new cyber adversary targeting Israeli government and IT businesses, tracked as ...
As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...
The technology for next-generation optical discs already exists - the real question is whether it'll ever trickle down to ...
Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that ...
A new study reveals experimental drug XL20 crosses the blood-brain barrier to stop toxic TDP-43 clumping in ALS.
To date, the company has raised over $34 million from investors and operates a 15-person team at facilities at Johns Hopkins Medical Campus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results